PI-LAB-2025-203

Retatrutide, Independent Lab Report

Retatrutide 5mg · Northwind Telehealth

Failed

Independent testing verdict Fail

This product failed independent verification.

Sample failed verification: 58.2% measured purity against a ≥98% claim, with 98.0% of labelled content.

Identity verified
No

The labelled compound was not confirmed

Measured purity
58.2%

Label claimed ≥98%

Content accuracy
98%

4.9mg measured against 5mg claimed

Test recency
Older result

Published 20 months ago

Specimen PI-LAB-2025-203 Tested by Vantage Analytical Labs 8 samples tested from this company Purity & Testing score 81/100

Full laboratory evidence Findings table, methodology, chain of custody and the original report

Findings

Metric Label claim Measured Assessment
Purity (HPLC) ≥ 98% 58.2% Fails claim
Identity (MS) Retatrutide Not confirmed Identity failure
Content 5 mg 4.9 mg Within 5% of label

Methodology & chain of custody

RP-HPLC purity with electrospray ionisation mass confirmation.

The sample was purchased anonymously through standard retail checkout and shipped to an unaffiliated address, then logged, photographed, and forwarded under chain-of-custody documentation to Vantage Analytical Labs. See our full testing methodology.

Lot / batch
A5159-25
Purchased
Analysed
Published
Laboratory
Vantage Analytical Labs
Test type
Purity & identity

Testing notes

Result confirmed on a second sample from a separate lot at a second laboratory before publication.

Original laboratory report: PI-LAB-2025-203-report.pdf (document delivery arrives with the production storage backend)

More Tests, Northwind Telehealth

Amycretin
Purity 97.5% Verified
Tirzepatide (Compounded)
Purity 97.4% Verified
Pemvidutide
Purity 96.5% Verified

More Tests, Retatrutide

Retatrutide Vector Peptide Supply
Purity 97.6% Verified
Retatrutide NextGen Peptides
Purity 99.7% Verified
Retatrutide Cardinal Metabolic Clinic
Purity 93.7% Verified